MX2024004725A - Metodos novedosos. - Google Patents

Metodos novedosos.

Info

Publication number
MX2024004725A
MX2024004725A MX2024004725A MX2024004725A MX2024004725A MX 2024004725 A MX2024004725 A MX 2024004725A MX 2024004725 A MX2024004725 A MX 2024004725A MX 2024004725 A MX2024004725 A MX 2024004725A MX 2024004725 A MX2024004725 A MX 2024004725A
Authority
MX
Mexico
Prior art keywords
treatment
novel methods
methods
carbolines
fentanyl
Prior art date
Application number
MX2024004725A
Other languages
English (en)
Spanish (es)
Inventor
Peng Li
Gretchen Snyder
Allen A Fienberg
Robert E Davis
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2024004725A publication Critical patent/MX2024004725A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024004725A 2021-10-19 2022-10-14 Metodos novedosos. MX2024004725A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163262732P 2021-10-19 2021-10-19
PCT/US2022/078177 WO2023069880A1 (en) 2021-10-19 2022-10-14 Novel methods

Publications (1)

Publication Number Publication Date
MX2024004725A true MX2024004725A (es) 2024-05-10

Family

ID=86058575

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004725A MX2024004725A (es) 2021-10-19 2022-10-14 Metodos novedosos.

Country Status (10)

Country Link
US (1) US20240415832A1 (https=)
EP (1) EP4419523A4 (https=)
JP (1) JP2024539106A (https=)
KR (1) KR20240089771A (https=)
CN (1) CN118556058A (https=)
AU (1) AU2022368858A1 (https=)
CA (1) CA3235356A1 (https=)
IL (1) IL312165A (https=)
MX (1) MX2024004725A (https=)
WO (1) WO2023069880A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7520013B2 (ja) 2018-12-17 2024-07-22 イントラ－セルラー・セラピーズ・インコーポレイテッド 置換複素環縮合γ－カルボリンの合成
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Synthesis of condensed gamma-carbolines and converted heterocycles
JP7649743B2 (ja) 2018-12-21 2025-03-21 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP4680244A1 (en) 2023-03-17 2026-01-21 Norwegian University Of Life Sciences Serotonin 5ht2a receptor antagonist for use in treating side effects resulting form mu opioid receptor agonist overdose
WO2026011136A1 (en) * 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2026011166A1 (en) * 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023062A1 (en) * 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
EP3833346A4 (en) * 2018-08-08 2022-08-03 Torralva Medical Therapeutics LLC Compositions for opiate and opioid prevention and reversal, and methods of their use
JP7649743B2 (ja) * 2018-12-21 2025-03-21 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN118105390A (zh) * 2019-01-23 2024-05-31 细胞内治疗公司 治疗成瘾的方法
JP7397095B2 (ja) * 2019-05-07 2023-12-12 ニーサム・ラボラトリーズ・インコーポレイテッド オピオイド受容体アンタゴニストプロドラッグ
JP2025509569A (ja) * 2022-03-14 2025-04-11 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物

Also Published As

Publication number Publication date
US20240415832A1 (en) 2024-12-19
WO2023069880A1 (en) 2023-04-27
KR20240089771A (ko) 2024-06-20
EP4419523A4 (en) 2025-09-17
IL312165A (en) 2024-06-01
EP4419523A1 (en) 2024-08-28
AU2022368858A1 (en) 2024-05-02
JP2024539106A (ja) 2024-10-28
CA3235356A1 (en) 2023-04-27
CN118556058A (zh) 2024-08-27

Similar Documents

Publication Publication Date Title
MX2024004725A (es) Metodos novedosos.
MX2025009723A (es) Metodos de tratamiento contra adicciones
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12017501421B1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MY202884A (en) Compounds useful in hiv therapy
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
NZ778223A (en) Modified release tablet formulations containing phosphodiesterase inhibitors
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2023014530A (es) Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo.
MX2024006105A (es) Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme.
MX2018014185A (es) Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.
PH12017501668A1 (en) Bace1 inhibitors
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
JOP20230099A1 (ar) تركيبات صيدلية
MY209771A (en) Compounds for use in the treatment of fascioliasis
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
EA202191384A1 (ru) 3,3-дифтораллиламины или их соли и содержащие их фармацевтические композиции
MX2019001320A (es) Composicion y uso de un peptido.